54% NON DILUTABLE RESTRICTED/CONVERSION/ SOME/ BSSP increase in the AS: Two Billion Two Hundred Twenty Million Eight Hundred Sixty Three Thousand Four Hundred and Four (2,220,863,404)

BSSP/Canteck Pharma 8-K filed with SEC:
http://www.sec.gov/Archives/edgar/data/149502...-index.htm

http://www.sec.gov/Archives/edgar/data/149502...form8k.htm


On April 19, 2016, Two Billion Two Hundred Twenty Million Eight Hundred Sixty Three Thousand Four Hundred and Four (2,220,863,404) shares of
the Company’s Common Restricted Stock were agreed to be issued to Canteck Pharma, Inc., representing 54.05% of the issued and
outstanding shares of Common Stock, in behalf of the Purchase Agreement with Cantech.
The shares shall have non dilutable provisions.

BSSP/
Canteck Pharma Sales Agreement filed with the SEC:
http://www.sec.gov/Archives/edgar/data/149502.../ex101.htm


Two Billion Two Hundred Twenty Million Eight Hundred Sixty Three Thousand Four Hundred and Four (2,220,863,404) (the “Purchase Shares”) of REVE TECHNOLOGIES, INC.(“BSSP”) restricted common shares.
The Purchase Shares are to carry a non-dilutable designation.